ReviewJournal of nanobiotechnology2026
Nano-PROTACs for precision medicine: engineering strategies for enhanced targeting and potency.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma.Cells · 2026Review
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality that leverages the endogenous ubiquitin-proteasome system (UPS) to achieve targeted protein degradation. These heterobifunctional molecules facilitate the recruitment of E3 ubiquitin ligases to a protein of interest (POI), promoting its ubiquitination and subsequent proteasomal degradation. In contrast to conventional inhibitory approaches, PROTACs operate catalytically, enabling the degradation of a wide spectrum of targets-including those harboring drug-resistant mutations-at significantly lower doses. These attributes have positioned PROTACs as promising agents, particularly in oncology, where their efficiency and broad applicability have been increasingly demonstrated. Nonetheless, clinical translation of PROTACs faces challenges such as poor bioavailability, insufficient tumor-specific accumulation, and off-target effects. The integration of nanomedicine-based delivery platforms offers a viable path to overcome these limitations by enhancing drug stability, improving tissue selectivity, and reducing systemic toxicity. This review outlines the rational design principles underlying nano-PROTACs, highlights recent advances in nanoformulations aimed at optimizing their delivery and efficacy, discusses emerging combination regimens and innovative design strategies, and critically assesses the translational challenges and future directions of nano-PROTACs. Overall, nano-PROTAC technology has pioneered a brand-new approach in the field of disease treatment, providing unprecedented opportunities for precision medicine and personalized disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.